Should I buy or sell Bausch Health Companies stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares. View BHC analyst ratings or view top-rated stocks .

What is Bausch Health Companies' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Bausch Health Companies' shares. Their BHC share price targets range from C$9.00 to C$9.00. On average, they expect the company's share price to reach C$9.00 in the next year. This suggests that the stock has a possible downside of 24.0%. View analysts price targets for BHC or view top-rated stocks among Wall Street analysts .

How have BHC shares performed in 2024?

Bausch Health Companies' stock was trading at C$10.63 at the start of the year. Since then, BHC shares have increased by 11.4% and is now trading at C$11.84. View the best growth stocks for 2024 here .

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BHC earnings forecast .

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (TSE:BHC) announced its earnings results on Thursday, February, 22nd. The company reported $1.55 earnings per share for the quarter, beating analysts' consensus estimates of $1.36 by $0.19. The company had revenue of $3.28 billion for the quarter, compared to analysts' expectations of $3.05 billion. Bausch Health Companies had a negative net margin of 6.76% and a negative trailing twelve-month return on equity of 686.52%.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Chesapeake Energy (CHKAQ) , Enbridge (ENB) , Aurora Cannabis (ACB) , Manulife Financial (MFC) , BlackBerry (BB) , Bank of Nova Scotia (BNS) , Toronto-Dominion Bank (TD) , Nutrien (NTR) , Suncor Energy (SU) and ARC Resources (ARX) .

How do I buy shares of Bausch Health Companies?

Shares of BHC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:BHC

Bausch Health Companies (BHC) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free BHC Stock Alerts

C$11.84

-0.09 (-0.75%)

(As of 04/18/2024 ET)

Compare

Today's Range: C$11.61
▼
C$12.07
50-Day Range: C$10.93
▼
C$14.35
52-Week Range: C$7.56
▼
C$15.43

Volume: 389,948 shs
Average Volume: 361,878 shs
Market Capitalization: C$4.33 billion

P/E Ratio: N/A
Dividend Yield: 0.76%
Price Target: C$9.00

Stock Analysis Analyst Forecasts Chart Competitors Earnings Headlines Insider Trades

Get Bausch Health Companies alerts:

Bausch Health Companies MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 24.0% Downside
C$9.00 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.23 out of 5 stars

1.0

Analyst's Opinion

Consensus Rating
Bausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Bausch Health Companies has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for BHC.

0.0

Dividend Strength

Dividend Yield
Bausch Health Companies has a dividend yield of 0.76%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Bausch Health Companies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BHC.

1.9

News and Social Media Coverage

News Sentiment
Bausch Health Companies has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
Search Interest
42 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bausch Health Companies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.18% of the stock of Bausch Health Companies is held by insiders.
Percentage Held by Institutions
81.00% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Bausch Health Companies is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bausch Health Companies is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Bausch Health Companies has a PEG Ratio of 0.21. PEG Ratios below 1 indicate that a company could be undervalued.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Bausch Health Companies Stock (TSE:BHC)

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

BHC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BHC Stock News Headlines

April 11, 2024 | finanznachrichten.de

Bausch Health Companies Inc.: Bausch Health to Announce First-Quarter 2024 Results on May 2

April 11, 2024 | seekingalpha.com

Bausch Health seesaws after appeals court affirms ruling in Norwich patent case

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 11, 2024 | msn.com

Bausch Health pares gain after appeals court affirms ruling in Norwich patent case

April 11, 2024 | finance.yahoo.com

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029

April 11, 2024 | finanznachrichten.de

Bausch Health Companies Inc.: Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

April 8, 2024 | nasdaq.com

TSX Recovers After Early Setback, Ends Slightly Down

April 5, 2024 | theglobeandmail.com

Bausch Health Companies: Top 10 Undervalued Growth Stocks on TSX (BHC)

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 3, 2024 | finance.yahoo.com

/C O R R E C T I O N from Source -- Canadian Investment Regulatory Organization (CIRO) - Halts/Resumptions/

April 1, 2024 | finance.yahoo.com

Breakeven Is Near for Bausch Health Companies Inc. (NYSE:BHC)

March 28, 2024 | finance.yahoo.com

Global Immunoprecipitation Testing Market Industry Trends & 10 Year Growth Forecasts 2019-2029

March 13, 2024 | seekingalpha.com

STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade

March 1, 2024 | ca.finance.yahoo.com

BHC Mar 2024 8.500 call

March 1, 2024 | finanznachrichten.de

Bausch Health Companies Inc.: Bausch Health Companies to Present at Cowen Annual Health Care Conference

February 24, 2024 | msn.com

Bausch Health Companies (BHC) Price Target Increased by 5.99% to 6.99

February 24, 2024 | finance.yahoo.com

Bausch + Lomb Corporation (NYSE:BLCO) Yearly Results: Here's What Analysts Are Forecasting For This Year

February 23, 2024 | markets.businessinsider.com

RBC Capital Maintains Sector Perform Rating for Bausch Health Companies: Here's What You Need To Know

February 23, 2024 | markets.businessinsider.com

Bausch Health Companies: Sell Rating Justified by Modest Growth Outlook and Persistent Uncertainties

February 23, 2024 | finance.yahoo.com

Bausch Health Companies Inc. (NYSE:BHC) Q4 2023 Earnings Call Transcript

February 22, 2024 | benzinga.com

Looking At Bausch Health Companies's Recent Unusual Options Activity

February 22, 2024 | finanznachrichten.de

Bausch Health Companies Inc.: Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

February 22, 2024 | msn.com

Bausch Health Companies beats top-line and bottom-line estimates; initiates FY24 outlook

February 22, 2024 | finance.yahoo.com

Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

February 22, 2024 | finance.yahoo.com

Bausch Health Companies Inc. Reports Revenue Growth Amidst Net Losses in Q4 and Full-Year 2023

February 22, 2024 | finance.yahoo.com

Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates

February 19, 2024 | finance.yahoo.com

Insights Into Bausch (BHC) Q4: Wall Street Projections for Key Metrics

See More Headlines

Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: TSE:BHC
CUSIP: N/A
CIK: N/A
Web: www.valeant.com
Phone: 514-744-6792
Fax: N/A
Employees: 20,270
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$9.00
High Stock Price Target: C$9.00
Low Stock Price Target: C$9.00
Potential Upside/Downside: -24.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($2.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 2.39
P/E Growth: 0.21
Net Income: C$-592,000,000.00
Net Margins: -6.76%
Pretax Margin: N/A
Return on Equity: -686.52%
Return on Assets: 3.82%

Debt

Debt-to-Equity Ratio: 7,583.76
Current Ratio: 1.30
Quick Ratio: 0.58

Sales & Book Value

Annual Sales: C$8.76 billion
Price / Sales: 0.49
Cash Flow: C$1.53 per share
Price / Cash Flow: 7.76
Book Value: C($2.80) per share
Price / Book: -4.23

Miscellaneous

Outstanding Shares: 365,410,000
Free Float: N/A
Market Cap: C$4.33 billion
Optionable: Not Optionable
Beta: 0.83

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Thomas J. Appio (Age 62)
CEO & Director
Comp: $6.43M
Ms. Seana Carson (Age 51)
Executive VP & General Counsel
Comp: $978.6k
Mr. John S. Barresi (Age 51)
Senior VP, Controller, Chief Accounting Officer & Interim CFO
Mr. Mirza Dautbegovic
Senior VP & COO
Mr. Josh Coyle
Senior Vice President of Sales & Salix
Ms. Kathleen Fitzpatrick
Senior VP & Chief HR Officer
Dr. Tage Ramakrishna M.D. (Age 50)
Chief Medical Officer and President of R&D
Mr. Jeff Hartness
Executive VP of Market Access, Commercial Operations, Neurology, Generics & Government Affairs
Dr. Graham Jackson
Senior VP & Chief Quality Officer
Mr. Cees Heiman
Senior Vice President of Europe & Canada

Key Competitors

View All Competitors

BHC Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings or view top-rated stocks.
What is Bausch Health Companies' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price objectives for Bausch Health Companies' shares. Their BHC share price targets range from C$9.00 to C$9.00. On average, they expect the company's share price to reach C$9.00 in the next year. This suggests that the stock has a possible downside of 24.0%.
View analysts price targets for BHC or view top-rated stocks among Wall Street analysts.
How have BHC shares performed in 2024?: Bausch Health Companies' stock was trading at C$10.63 at the start of the year. Since then, BHC shares have increased by 11.4% and is now trading at C$11.84.
View the best growth stocks for 2024 here.
When is Bausch Health Companies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BHC earnings forecast.

How were Bausch Health Companies' earnings last quarter?: Bausch Health Companies Inc. (TSE:BHC) announced its earnings results on Thursday, February, 22nd. The company reported $1.55 earnings per share for the quarter, beating analysts' consensus estimates of $1.36 by $0.19. The company had revenue of $3.28 billion for the quarter, compared to analysts' expectations of $3.05 billion. Bausch Health Companies had a negative net margin of 6.76% and a negative trailing twelve-month return on equity of 686.52%.
What other stocks do shareholders of Bausch Health Companies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Chesapeake Energy (CHKAQ), Enbridge (ENB), Aurora Cannabis (ACB), Manulife Financial (MFC), BlackBerry (BB), Bank of Nova Scotia (BNS), Toronto-Dominion Bank (TD), Nutrien (NTR), Suncor Energy (SU) and ARC Resources (ARX).
How do I buy shares of Bausch Health Companies?: Shares of BHC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:BHC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bausch Health Companies (BHC) Stock Price, News & Analysis

Bausch Health Companies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

Company Ownership

Earnings and Valuation

About Bausch Health Companies Stock (TSE:BHC)

BHC Stock Price History

BHC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BHC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™